Antibody strategy to augment versatile immune cells sparks investment in French biotech
A small fraction of versatile immune cells — prized for their ability to hack the tumor microenvironment — are shaping up to be the next wave of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
